A mutant of recombinant tissue-type plasminogen activator (rt-PA), obtained by deletion of residues Lyss to Gly302 [rt-PA del(K296-G302)], was previously shown t o be resistant t o inhibition by plasminogen activator inhibitor-1 (PAI-1) (Madison et ai, Nature 339:721, 1989). This mutant was obtained by expression of its cDNA in Chinese hamster ovary cells and purification t o homogeneity from conditioned cell culture medium. It was obtained as a single chain molecule with amidolytic activity, specific fibrinolytic activity, and binding t o fibrin and lysine, which were comparable or somewhat lower than those of wild-type rt-PA obtained in the same expression system. The plasminogen-activating potential of rt-PA del(K296-G302) in the presence of CNBr-digested fibrinogen was about twofold lower than that of wild-type rt-PA. The inhibition rate of rt-PA del(K296-G302) by recombinant PAL1 (rPAI-1) was more than 500-fold lower than that of wild-type rt-PA. In a human plasma milieu in vitro, rt-PA del(K296-G302) induced dose-dependent lysis of a '%fibrin-labeled plasma clot; equi-effective concentrations (causing 50% clot lysis in 2 hours) were 0.28 pg/mL and 0.36 pg/mL for mutant and wild-type rt-PA, respectively. In this system, addition of rPAI-1 to the plasma resulted in a concentrationdependent reduction of the fibrinolytic potency of rt-PA del(K296-G302) and of rt-PA; a 50% reduction required 2.4 pg/mL and 0.15 pg/mL rPAI-1, respectively. Continuous
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ISSUE-TYPE plasminogen activator (t-PA) is the phys-
T iologic activator of the fibrinolytic system in blood and plays an important role in the removal of fibrin from the vascular tree.' Human t-PA is a serine proteinase with a molecular weight (M,) of about 70,000 consisting of a single polypeptide chain of 527 amino acids with Ser as the NH,-terminal amino acid.' Plasmin converts t-PA to a two-chain form by hydrolysis of the Arg275-Ile276 peptide bond.' t-PA has a significant affinity for fibrin, and preferentially activates plasminogen at the fibrin surface, probably as a result of the formation of a cyclic ternary complex between fibrin, plasminogen, and t-PA.' This fibrin-specific mechanism of action of t-PA has triggered great interest in its use as a thrombolytic agent, and, over the last years, recombinant t-PA (rt-PA) has been used successfully to recanalize thrombosed blood vessels in patients with thromboembolic disease.' As do other currently available thrombolytic agents, rt-PA suffers from a number of limitations, including resistance to reperfusion within 90 minutes in 15% to 25% of patients with acute myocardial infarction, acute coronary reocclusion in 5% to 25% of patients, and significant bleeding with a frequency of intracerebral bleeding of approximately Therefore, the quest for PAS with better thrombolytic profiles remains open.
PAS are inhibited in plasma by specific plasminogen activator inhibitors (PAI), mainly by PAI-1, which rapidly inhibits both single-chain and two-chain t-PA.5 PAI-1 is a member of the serpin superfamily, with reactive site peptide bond Arg'46-Met347.b Madison et al' have identified specific amino acids in t-PA (residues L~s'~~-His-Arg-Arginfusion of mutant or wild-type rt-PA over 60 minutes in hamsters with a '%labeled plasma clot in the pulmonary artery resulted in dose-dependent clot lysis, with a thrombolytic potency (percent clot lysis per milligram of compound administered per kilogram of body weight) and a specific thrombolytic activity (percent clot lysis per microgram per milliliter steady state rt-PA-related antigen level in plasma) that were not significantly different. Bolus injection in hamsters of 1 mg/kg rPAI-1 followed by bolus injection of 1 mg/ kg rt-PA del(K296-G302) or wild-type rt-PA resulted in neutralization of the thrombolytic potency of wild-type rt-PA, while the mutant retained approximately half of its thrombolytic potency. These results indicate that rt-PA del(K296-G302), with a known resistance t o inhibition by rPAI-1 in purified systems, maintains this property both in a plasma milieu in vitro and in an experimental animal model of thrombolysis in vivo. In the absence of added rPAI-1, the thrombolytic potency and specific thrombolytic activity of rt-PA del(K296-G302) is comparable with that of wild-type rt-PA. Thus, rt-PA del(K296-G302) may offer advantages as a thrombolytic agent in clinical conditions in which high PAL1 levels may contribute t o resistance t o thrombolysis or predispose t o reocclusion.
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Ser-Pro-Gly'"' and ArgM4) that are involved in its interaction with the inhibitor PAI-1 but not with the substrate plasminogen. Mutations or deletions in the region comprising residues 296 to 304 of t-PA were shown to confer resistance to purified PAI-l.? These results were confirmed and extended by Bennett et a1,8 who suggested that the 296 to 304 region in t-PA is the only one in which PAI-1 resistance can be induced by site-directed mutagenesis.
In the present study, we have constructed and purified a similar rt-PA mutant, obtained by deletion of residues LysZyb to GI?* [rt-PA del(K296-G302)], to evaluate its biologic properties in a plasma milieu in vitro and its thrombolytic and pharmacokinetic properties in a hamster pulmonary embolism model.
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LI ETAL
MATERIALS AND METHODS

Proteerns and reagents.
Recombinant single-chain human t-PA (Actilyse) was obtained from Boehringer Ingelheim (Ingelheim, Germany), or was homemade by expression of t-PA cDNA in Chinese hamster ovary (CHO) cells as described elsewhere.' Two-chain rt-PA' was prepared by overnight treatment of rt-PA (final concentration, 25 pmoliL) at 4°C in 0.05 moliL Tris-HC1 buffer, pH 7.4, containing 0.038 mol/L NaCI, 0.1 mol/L arginine, and 0.01% Tween 80, with plasmin-sepharose (5% molar ratio), which was removed by filtration. Plasmin-sepharose was prepared from plasminogen-sepharose as described elsewhere." Human plasminogen, fibrinogen, and CNBr-digested fibrinogen were obtained and characterized as described elsewhere." Recombinant PAL1 (rPAI-1) was obtained and characterized as described previous1y.l' It was reactivated by incubation with 4 moliL guanidinium chloride for 20 minutes at 37T, followed by overnight dialysis at 4°C against phosphate-buffered saline (PBS). Its specific activity, as determined by titration against rt-PA (Actilyse), ranged between 100,000 and 220,000 IUimg for different preparations. rPAI-1 concentrations reported in this study represent active protein.
Human plasma was pooled fresh frozen plasma from at least five healthy blood donors. Aprotinin (Trasylol) was purchased from Bayer (Leverkusen, Germany), D-Val-Leu-Lys-p-nitroanilide (S-2251) and D-Ile-Pro-Arg-p-nitroanilide (S-2288) from KabiVitrum (Brussels, Belgium), and D-Phe-Pro-Arg-CH'CI (PPACK) from Calbiochem (La Jolla, CA)." PPACK was dissolved in 1 mmol/L HCI and Its concentration was determined by amino acid analysis. 12sI-labeled fibrinogen was purchased from Amersham (Buckinghamshire, UK). Restriction and DNA modifying enzymes were obtained from GIBCOiBRL (Ghent, Belgium), Boehringer Pharma (Brussels, Belgium), or New England Biolabs (Boston, MA).
Construction and erpression of rt-PA del(k296-G302) cDNA. The isolation of t-PA cDNA and the construction of pt-PAsh, containing the complete coding sequence, 9 nucleotides of 5'-untranslated sequence, and 61 nucleotides of 3'-untranslated sequence, has been described elsewhere.' This t-PA cDNA was subcloned in M13mp18 and used as template DNA for subsequent mutagenesis. The chemically synthesized deletion oligonucleotide, 5'-ACAGGAACCGCTCGGCAAAGATGGC-3' (complementary to nucleotides 1063 to 1074 and 1096 to 1108 of the t-PA cDNA sequence') was phosphorylated using T4 polynucleotide kinase. Mutagenesis and selection for mutant phage by in situ hybridization were performed as described.14 Positive plaques were selected for restriction enzyme digestion and sequencing to verify the mutation and to rule out any undesired mutations.
The expression plasmid containing the cDNA coding for rt-PA del(K296-G302) was used for stable transfection of CHO cells as described.Is Transfected cells were selected with 400 FgimL Geneticin (GIBCOIBRL). Geneticin-resistant colonies were screened for t-PA-related antigen secretion by enzyme-linked lmmunosorbent assay (ELISA)" and a suitable cell line was chosen for large scale production, as described previo~sly.'~ Punjcation of &-PA del(K296-G302) from conditioned cell culture medium. rt-PA del(K296-G302) was purified by chromatography on zinc chelate-sepharose essentially as described," followed by immunoadsorption on an insolubilized murine monoclonal antibody (MoAb) against t-PA (MA-1C8).lS Elution was performed with 1.6 moliL KSCN and the fractions containing t-PA-related antigen were pooled and dialyzed against 0.3 moliL NaC1, 0.1 mol/L arginine, 0.02 mol/L Tris-HC1 buffer, pH 7.4, containing 0.01% Tween 80 and 10 KlUimL aprotinin. Before use, aprotinin was removed by extensive washing on a Centricon 30 microconcentrator (Amicon, Danvers, MA) with 0.05 moliL Tris-HCI buffer, pH 7.4, containing 0.038 moliL NaCI, 0.1 mol/L arginine and 0.01% Tween 80.
DNA sequence analysis was performed according to Sanger et al." Amino acid analysis, after removal of arginine by extensive washing with 10% acetic acid on a Centricon 30 microconcentrator, was performed on a Beckman 119CL amino acid analyzer after 20 hours of hydrolysis in 6 mol/L HCI at 110°C in sealed ampoules. Specific fibrinolytic activities were determined on bovine fibrin plates" by comparison with the 2nd International Reference Preparation for t-PA (code 86/670),2' obtained from the National Institute for Biological Standards and Control (London, UK). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed on 10% to 15% gradient gels without reduction or after reduction of the samples with dithioerythritol, using the Phast System (Pharmacia, Uppsala, Sweden). Total t-PA antigen was measured with a specific ELISA" calibrated with rt-PA moieties of which the protein concentration was determined by amino acid analysis. Alternatively, t-PA protein concentration was determined with the Bradford assay.22 PAL1 antigen, PAI-1 activity, and t-PAiPAI-1 complexes were determined with specific MoAb-based ELISAS." Fibrinogen levels in plasma samples were determined with a clotting rate assayz4 and a,-antiplasmin levels with a chromogenic substrate method." The effect of fibrin on the initial activation rate of plasminogen by the rt-PA moieties was evaluated by incubation of plasminogen (final concentration, 5.0 p,mol/L) at 37°C in 0.1 moliL phosphate buffer, pH 7.3, with CNBr-digested fibrinogen (final concentration, 0.05 to 2.0 FmoliL) before the addition of the enzyme (final concentration, 20 nmoliL). Before use, arginine was removed from the rt-PA moieties by extensive dialysis. The plasmin generated (0 to 5 minutes) was measured as described above after 20-fold dilution of the sample, and initial activation rates were expressed as nanomoles per liter per second.
Alternatively, activation of plasminogen (final concentration, 1.0 p,mol/L) by the rt-PA moieties (final concentration, 5 nmoliL) in the presence of CNBr-digested fibrinogen (final concentration, 2.0 pmoliL) was monitored over a 30-minute period, as described above.
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Kinetics of the inhibition of rt-PA del(K296-G302) by rPAI-I or PPACK in purified systems. The inhibition rate of single-chain or two-chain forms of rt-PA del(K296-G302), wild-type rt-PA, or Actilyse by rPAI-1 was measured in the presence of S-2288 by continuous monitoring of the absorbance at 405 nm, as described by Chmielewska et al?' All measurements were performed at 37°C in 0.05 mol/L Tris-HC1 buffer, pH 7.4, containing 0.038 moliL NaCl and 0.01% Tween 80 using S-2288 at a final concentration of 0.5 mmol/L. For the single-chain rt-PA moieties the concentrations of reagents used were 4 to 5 nmol/L enzyme with 5 to 6 nmol/L rPAI-1 for Actilyse and wild-type rt-PA and 120 nmol/L rPAI-1 for rt-PA del(K296-G302). For the two-chain rt-PA moieties, 7.0 nmol/L enzyme was used with 9 nmol/L rPAI-1 for Actilyse and wild-type rt-PA, and 2.6 nmoliL enzyme with 65 nmol/L rPAI-1 for rt-PA del(K296-G302). The second order association rate constant of the reactions (k,) was determined using the classical equation for second order reactions (assuming a 1:l stoichiometric interaction between rPAI-1 and enzyme) as described previo~sly,~' or, for the experiments under pseudo-first order conditions, as the ratio of the pseudefirst-order rate constant (determined from semilogarithmic plots of residual enzyme activity versus time) and the inhibitor concentrations used. Residual enzyme activities, determined at different time intervals, were corrected for the effect of S-2288 on the inhibition reaction," The inhibition rate of single-chain or two-chain forms of rt-PA del(K296-G302), wild-type rt-PA, or Actilyse by PPACK was measured under pseudefirst-order conditions at 37°C in 0.05 mol/L Tris-HC1 buffer, pH 7.4, containing 0.038 mol/L NaCl and 0.01% Tween 80. The enzymes were incubated at a final concentration of 250 to 600 nmol/L for single-chain forms or 50 to 250 nmol/L for two-chain forms with PPACK (final concentration, 0.5 to 2.5 pmol/L). Residual t-PA activities were measured at different time intervals with S-2288 (final concentration, 0.5 mmol/L) after 10-fold dilution of samples. The inhibition rate constant (efficiency index, expressed as L . mol-' . s-') was determined as described above.
Singlechain or two-chain forms (final concentration, 1 pg/mL) of rt-PA del(K296-G302), wild-type rt-PA, or Actilyse were incubated at 37°C in pooled normal human plasma (PAI-1 activity, 5 ngimL). At different time intervals (0, 10, 20,30,45, 60,90, and 120 minutes), 0.2-mL samples were removed, diluted 20-fold, and cooled on ice. The euglobulins were immediately precipitated at pH 5.2 and the precipitates (after centrifugation) were redissolved in 0.2 mL 0.05 mol/L sodium barbital-0.1 mol/L barbituric acid buffer, pH 7.75, containing 0.01% Tween 80. The residual t-PA activity was measured on bovine fibrin plates and the half-life time ( t x ) was determined from linear semilogarithmic plots of residual activity versus time.
Alternatively, single-chain or two-chain forms of rt-PA del(K296-G302), wild-type rt-PA, or Actilyse (final concentration, 1 nmol/L) were added to pooled human plasma supplemented with active rPAI-1 to a concentration of 0.7 nmol/L. At different time intervals (0 to 15 minutes) samples were removed, diluted fivefold in buffer containing PPACK (final concentration, lo-' moliL), and t-PA/ PAI-1 complexes were measured by ELISA.U Plasminogen-depleted human fibrinogen (final concentration, 0 to 3.2 mg/mL) in 0.05 moliL Tris-HCI buffer, pH 7.4, containing 0.038 moliL NaCI, 0.01% Tween 80, and Inhibition of rt-PA deI(K296-G302) in human plasma.
Binding to punfied fibrin. 1 mg/mL bovine serum albumin was mixed with the dialyzed rt-PA moieties (final concentration, 200 ngimL). The mixture was clotted by addition of thrombin to a final concentration of 20 NIH unitsiml. After 1 minute of incubation at 3 7 T , thrombin was inactivated by the addition of D-Ile-Pro-Arg-CH,C1 (final concentration, 10 pmoliL), and the samples were centrifuged for 1 minute at 10,OOQg. The concentration of rt-PA-related antigen in the supernatants was determined by ELISA.
The different rt-PA moieties (final concentration, 200 ngimL), dialyzed extensively to remove arginine, were incubated on a tilting table for 2 hours at room temperature in PBS containing 1 mg/mL albumin and 0.01% Tween 80, with different amounts (0 to 333 pL) of a suspension of lysine-sepharose (300 mg dry lysine-sepharose/mL or 30%, wtivol) in a total volume of 0.5 mL. After centrifugation, residual rt-PA antigen in the supernatants was measured by ELISA.
Fibrinolytic and fibrinogenolytic properties in a human plasma milieu in vitro. The relative fibrinolytic potency and fibrin specificity of the single-chain rt-PA moieties (final concentration, 0.025 to 6.4 pgimL) was measured in a system composed of a 60 p L 'ZSI-fibrin-labeled human plasma clot, suspended in 0.5 mL citrated human plasma, essentially as described elsewhere.2x The concentration of PA required to obtain 50% clot lysis in 2 hours (C5J was determined from plots of percent lysis versus the concentration of PA. Residual fibrinogen levels at C,, were determined from plots of residual fibrinogen at 2 hours versus the concentration of PA. Fibrin clot lysis induced by an equipotent concentration of rt-PA moiety was also evaluated iri human plasma supplemented with reactivated rPAI-1 (final concentration, 0.032 to 10 pg/mL).
In addition, systemic activation of the fibrinolytic system in normal human plasma by the single-chain rt-PA moieties (final concentration, 0.8 to 100imL) in the absence of fibrin was monitored by measuring residual fibrinogen levels. The concentration of PA required to obtain 50% fibrinogen degradation within 2 hours was determined graphically from dose-response curves.
Thrombolytic properties in hamsters with pulmonaiy embolnm. The thrombolytic potency of single-chain rt-PA del(K296-G302) was compared with that of single-chain wild-type rt-PA and Actilyse in hamsters with experimental pulmonary embolism." In brief, a 25 pL '2SI-fibrin-labeled human plasma clot was injected via the left jugular vein and clot lysis was performed by intravenous infusion over 60 minutes of PA at different doses, using a constant rate infusion pump. Thirty minutes after the end of the infusion, the extent of clot lysis was determined as the difference between the radioactivity initially incorporated in the clot and that recovered ex vivo in the heart and lungs. An isotope recovery balance was made by adding the radioisotope content recovered in the heart and lungs and that in the blood (multiplied with a factor 3 to correct for extravascular distribution) at the end of the experiments. Blood samples of 0.2 mL were drawn into trisodium citrate (0.011 mol/L final concentration) for measurement of fibrinogen (at 0 and 90 minutes), cqantiplasmin (at 0 and 90 minutes), and t-PA-related antigen (at 60 minutes).
The thrombolytic potency (clot lysis versus dose) and the specific thrombolytic activity (clot lysis versus plasma antigen level) of the agents were determined as follows. The individual values of the percent lysis (parameter y) versus dose in milligrams of compound per kilogram of body weight (parameter x), or of the percent lysis (parameter y) versus steady state plasma level in micrograms per milliliter (parameter x) were fitted with an exponentially transformed sigmoidal function Binding to lysine-sepharose.
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In additional experiments. hamsters were supplemented in rPAI-I by bolus injection of 1 mg/kg of reactivated rPAI-I. This procedure was followed immediately by bolus injection of either saline, 1 mglkgof rt-PAdel(K296G302). or 1 mg/kgof Actilyse. In separate experiments, clot lysis by bolus injection of 1 mglkg rt-PA del(K296G302) or of 1 mg/kg Actilyse, without addition of rPAI-I, was determined. Clot lysis was quantitated after 90 minutes by the ex vivo isotope recovery method, as described above, and the time course of clot lysis was monitored continuously dithioerythitol (e). Lane by external gamma counting, using a sodium iodide/thallium crystal.'" Blood samples for determination of t-PA-related antigen,'" rPAI-related antigen. or t-PA/PAI-I complex'3 were collected on trisodium citrate (0.01 1 mol/L final concentration) containing PPACK (final concentration. 5 x IO-' mol/L) after 0.5. 1. 5, 10. 30 . and 60 minutes. Blood samples without addition of PPACK were collected at time 0 and 90 minutes for determination of fibrinogen and a,-antiplasmin levels.
The pharmacokinetics of single-chain rt-PA del(K296G302) were compared with those of wild-type rt-PA and Actilyse after bolus injection of 0.10 mg/kg in groups of three hamsters. 1-PA-related antigen concentrations in plasma were measured at different time intervals and the results were plotted on semilogarithmic paper and fitted with a sum of two exponential terms, C(t) = Ae-"' + Be-"'by graphical curve peeling. Therefore, the linear terminal portion of the curves representing the logarithm of the antigen concentration versus time was extrapolated to yield the ordinate intercept B. This line had a slope -p.
The extrapolated values were subtracted from the initial values and these corrected data were fitted with a line that had a slope -a and an ordinate intercept A.
The following drug disposition parameters were calculated from the coefficients (A and B) and exponents (a and p) describing the disposition of t-PA-related antigen from plasma. using standard formulas derived by Gibaldi and Perrier"': volume of the central compartment (in milliliters) V, = dose/(A + B): extrapolated area Pharmacokinetic propeHies it1 hamsters. 
30
Time ( under the curve (in pg. min . mL-') AUC = A/@ + BIP; and plasma clearance (in mL . min-') C1, = dose/AUC.
The clearance (in mL.min-') during the steady state phase accompanying continuous intravenous infusion of the rt-PA moieties was also calculated from the ratio between the infusion rate (in nanograms per minute) and the steady state plasma concentration (in nanograms per milliliter), assuming a body weight of 100 g.
RESULTS
Construction
and expression of rt-PA del(K296-G302) cDNA. The rt-PA del(K296-G302) cDNA was produced by oligonucleotide directed deletion mutagenesis as described under Materials and Methods. The mutation was confirmed by DNA sequence analysis. Then the cDNA for rt-PA del(K296-G302) was inserted into the eukaryotic expression vector pCMpneo, as described." The sequence extending at least 80 bp on each side of the mutation was further confirmed by DNA double-stranded sequencing. The mutant cDNA/pCMpneo was transfected in CHO cells. The transfected cells were selected for resistance against geneticin and the stable expression colonies were (Fig lA, lane 2) . The purified protein was obtained primarily in its singlechain form, as evidenced by SDS-PAGE after reduction with dithioerythritol (Fig lB, lane 2) . The amino acid composition of rt-PA del(K296-G302) was compatible with the published amino acid sequence (not shown). The specific fibrinolytic activities measured on fibrin plates were (mean ? SEM of six determinations with two preparations) 120,000 & 18,000 IU/mg or 110,000 2 24,000 IU/mg for single-chain or two-chain forms of rt-PA del(K296-G302), as compared with 210,000 r 38,000 IU/mg or 130,000 ? 10,000 IUimg for single-chain or two-chain forms of wildtype rt-PA expressed in the same system and to 460,000 -C 29,000 IU/mg or 470,000 ? 11,000 IU/mg for single-chain or two-chain forms of Actilyse (Table 1 ). Our two-chain wild-type rt-PA thus has a lower specific activity than the single-chain wild-type rt-PA (P = .02), whereas this difference is not significant between single-chain and two-chain forms of rt-PA del(K296-G302) or Actilyse. Possibly, some rt-PA activity has been lost during plasmin treatment.
The K, and k, values for hydrolysis of the chromogenic substrate S-2288 by single-chain or two-chain rt-PA moieties, as determined by linear regression analysis of the data after Lineweaver-Burk transformation (r > .99), are summarized in Table 1 The catalytic efficiency for plasminogen activation of both single-chain rt-PA del(K296-G302) (0.17 t 0.01 x lo-' L . pmol-' . s-') and of its two-chain derivative (0.25 ? 0.01 L . pmol-' . s-') was fivefold to 10-fold lower than that of wild-type rt-PA. Addition of CNBr-digested fibrinogen resulted in a concentration-dependent stimulation of the initial activation rate of plasminogen by all rt-PA variants (not shown). The activation rate at infinite concentration of fibrin is determined from the inverse of the ordinate intercept in a double reciprocal plot of the activation rate versus the concentration of CNBr-digested fibrinogen (not shown). Table 1 summarizes these data and also shows the stimulation factor of CNBr-digested fibrinogen on plasminogen activation, obtained as the ratio of the initial activation rate in the presence of infinite fibrin concentration and the initial activation rate in the absence of fibrin. The initial rate of plasminogen activation in the presence of CNBrdigested fibrinogen was somewhat lower for rt-PA del(K296-G302) than for wild-type rt-PA, and was about fivefold lower than that of Actilyse. When plasminogen activation in the presence of CNBrdigested fibrinogen was monitored over a longer time period, it appeared that both single-chain and two-chain rt-PA del(K296-G302) showed a clear lag phase (Fig 2) . Maximal activation was obtained at later time points and was twofold to threefold lower than that of wild-type rt-PA or of Actilyse, respectively.
Kinetics of the inhibition of rt-PA del(K296G302) by rPAI-1 or PPACK in purified systems. The second-order rate constant for the inhibition of single-chain rt-PA del(K296-G302) by rPAI-1 was 560-or 850-fold lower than that for single-chain wild-type rt-PA or Actilyse, respectively; for the two-chain moiety these values were, respectively, 120-or 300-fold lower ( Table 2) single-chain rt-PA del(K296-G302) by PPACK was threefold slower than that of two-chain rt-PA del(K296-G302), but the inhibition rates were comparable with those of rt-PA and Actilyse.
Inhibition of rt-PA del(K296G302) in human plasma in vitro. After the addition to normal human plasma of single-chain or two-chain rt-PA moieties to a final concentration of 1 kg/mL, the plasma fibrinolytic activity, as measured in euglobulin fractions on fibrin plates, decreased slowly as a function of time. Semilogarithmic plots of residual rt-PA activity (mean of three independent determinations) versus time were linear (not shown): half-life times were 120 minutes, 120 minutes, or 60 minutes for singlechain forms of rt-PA del(K296-G302), wild-type rt-PA, or Actilyse, respectively, as compared with 90 minutes, 90 minutes, or 50 minutes for the corresponding two-chain forms.
Addition of 1 nmol/L of the single-chain or two-chain rt-PA moieties to human plasma supplemented with 0.7 nmol/L rPAI-1 resulted in rapid generation of t-PA/PAI-1 complexes for single-chain and two-chain rt-PA or Actilyse, whereas for single-chain and two-chain rt-PA del(K296-G302), virtually no complex was detected after 15 minutes [lo pmol/L or 26 pmol/L for single-chain or two-chain rt-PA del(K296-G302) as compared with 8 pmol/L in the plasma before addition of PA] ( Table 3 ).
All single-chain rt-PA moieties showed a concentration-dependent binding to fibrin (Fig 3) . Specificity of the binding is evidenced by the absence of binding of single-chain urokinase-type PA (not shown). At a fibrin concentration of 3.4 mg/mL, binding was (mean f SD; n = 3) 97% +-2% for rt-PA del(K296-G302) as compared with 91% f 1% for rt-PA and 99% f 2% for Actilyse. Figure 4 shows that all rt-PA moieties bind in a concentration-dependent way to lysine-sepharose with a maximal binding of about 60% at a comparable concentration of lysine-sepharose. Specificity of the binding is evidenced by the absence of binding of a,-antiplasmin (not shown).
Fibrinolytic and jibrinogenolytic properties in a human plasma milieu in vitro. All single-chain rt-PA moieties tested induced a time-and concentration-dependent lysis of a lZSI-fibrin-labeled human plasma clot immersed in human plasma. Equi-effective concentrations (causing 50% clot lysis in 2 hours) ( Fig SA) were (mean f SEM) 0.28 2 0.04 kg/mL (n = 5) for rt-PA del(K296-G302), as compared with 0.36 f 0.01 p,g/mL (n = 3) for rt-PA and with 0.17 f 0.006 pg/mL (n = 4) for Actilyse. At these concentrations of PA, residual fibrinogen levels after 2 hours were 93% f 2%, 98% f 1% or 90% f 2% for rt-PA del(K296-G302), wild-type rt-PA, or Actilyse (Fig 5B) .
Upon addition of reactivated rPAI-1 to human plasma, the fibrinolytic potency of an equi-effective dose of PA (yielding 75% clot lysis in 2 hours in normal plasma, see Fig  SA) was reduced to 50% with (mean of three determinations) 0.15 kg/mL rPAI-1 for wild-type rt-PA and with 0.16 kg/mL rPAI-1 for Actilyse, but this required 2.4 pg/mL rPAI-1 for rt-PA del(K296-G302) (Fig 6) .
In the absence of fibrin, the addition of all rt-PA moieties
Binding to fibrin.
Binding to lysine-sepharose. (8) The data represent mean t SEM of the number of experiments indicated in parentheses.
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From induced a time-and concentration-dependent fibrinogen breakdown (not shown), with 50% fibrinogen degradation in 2 hours with (mean of three determinations) 28 pg/mL for rt-PA del(K296-G302), as compared with 5.6 pg/mL for rt-PA and with 5.2 Fg/mL for Actilyse.
Thrombolytic properties in hamsters with pulmonary embolism. Dose-response curves of clot lysis after intravenous infusion over 60 minutes of single-chain forms of rt-PA del(K296-G302), wild-type rt-PA, or Actilyse in hamsters with pulmonary embolism induced with a human plasma clot are summarized in Table 4 . All three PAS caused a progressive dose-dependent degree of clot lysis. Steady state t-PA-related antigen concentrations in plasma ranged between 0.19 and 0.80 pg/mL for rt-PA del(K296-G302) at doses between 0.25 and 1.0 mg/kg, as compared with 0.05 to 0.47 p,g/mL with 0.063 to 0.50 mgikg wild-type rt-PA and with 0.025 to 0.32 Fg/mL with 0.032 to 0.50 mg/kg Actilyse. This resulted in 37% f 10% to 59% f 11% clot lysis with rt-PA del(K296-G302), 33% f 5% to 66% k 5% with wild-type rt-PA, and 34% f 4% to 84% f 6% with Actilyse. The isotope recovery balance ranged between 93% 2 6% and 120% 2 19% in all experimental groups, confirming that no significant parts of the thrombus were lost by embolization.
Fitting of the dose-response data with the individual values (clot lysis in percent versus dose in milligrams of compound administered per kilogram of body weight, or clot lysis in percent versus steady state plasma level of t-PA in micrograms per milliliter) with the exponentially transformed sigmoidal function (Fig 7) yielded values for c (maximal lysis achieved), b (dose or plasma antigen level at which maximal lysis occurs), and z (maximal rate of clot lysis), as summarized in Table 5 . The thrombolytic potency of single-chain rt-PA del(K296-G302) was somewhat but not significantly lower than that of wild-type rt-PA, as shown by both a lower z-value (69% f 20% v 150% f 36% lysis per milligram of compound administered per kilogram of body weight; P = .045) and a higher b-value (0.151 f 0.077 v 0.086 * 0.028 mgikg; P = .466). The specific thrombolytic activity of single-chain rt-PA del(K296-G302) was also somewhat lower than that of wild-type rt-PA, as shown by both a lower z-value (88% * 23% v 160% ? 49% lysis per microgram per milliliter plasma level; P = .161) and a higher b-value (0.129 ? 0.065 v 0.065 2 0.029 pg/mL; P = .413).
Actilyse had an approximately twofold higher thrombolytic potency than our homemade wild-type rt-PA (z = 310% f 42% lysis per milligram of compound administered per kilogram of body weight [P = .025]; b = 0.061 f 0.011 mg/kg [P = .316]) and an approximately threefold higher specific thrombolytic activity (z = 500% f 79% lysis per microgram per milliliter plasma level [P = .loo]; b = 0.032 f 0.007 pg/mL [P = .126]). This difference, which is statistically not very significant, may be due to the different production and/or purification procedures.
No significant systemic activation of the fibrinolytic system was induced by either agent. Fibrinogen levels at the end of the experiments were even somewhat increased both in the control groups and in the experimental groups (Table  4) . This finding may be the result of some hemodilution due to chasing of the plasma clot in the jugular vein with 1 mL saline. The sample used to determine the baseline fibrinFor personal use only. on November 11, 2017. by guest www.bloodjournal.org From ogen level in each animal was indeed taken immediately after the chasing with saline.
Thrombolytic properties in hamsters supplemented with rPAI-I. Table 6 summarizes the results of clot lysis and hemostasis analysis obtained with rt-PA del(K296-G302) and Actilyse in hamsters with pulmonary embolism supplemented with rPAI-1. Bolus injection of reactivated rPAI-1 at a dose of 1 mgikg (total protein concentration about 3 mg/kg) decreased clot lysis induced by subsequent bolus injection of 1 mgikg rt-PA del(K296-G302) from 44% ? 6% (in the absence of rPAI-1) to 21% 2 1% (P = .009). Under the same experimental conditions, clot lysis induced by bolus injection of 1 mgikg Actilyse was decreased from 69% f 10% to 6% f 1% (n = 4) after prior bolus injection of rPAI-1 (P < .OOl). Spontaneous clot lysis with injection of saline was decreased from 19% f 2% to 3% f 1% (P < .001) upon bolus injection of rPAI-1. Whereas in the absence of rPAI-1 clot lysis obtained with both rt-PA del(K296-G302) and Actilyse was significantly above the background of spontaneous clot lysis (P < .001 both), clot lysis after prior bolus injection of rPAI-1 was only significantly above background for rt-PA del(K296-G302) (P < .001) but not for Actilyse (P = .078). Thus, in the presence of rPAI-1, bolus injection of rt-PA del(K296-G302) at a dose of 1 mgikg induced significantly more clot lysis than Actilyse at the same dose (P < .001), whereas in the absence of rPAI-1, bolus injection of 1 mg/kg rt-PA del(K296-G302) induced somewhat less clot lysis than Actilyse (P = .072).
The isotope recovery balance in all experimental groups ranged between 98% 12% and 112% 2 6%. Fibrinogen and g-antiplasmin levels, determined 90 minutes after the bolus injections, were not significantly different from the baseline values in the different groups (Table 6 ). Figure 8 shows the time course of clot lysis (decrease of radioactivity in the clots) for the experiments without ( Fig  8A) or with (Fig 8B) bolus injection of rPAI-1, as monitored continuously by external gamma counting. The extent of clot lysis at 90 minutes in the absence of rPAI-1 was 16% 2 2% for the control experiments, as compared with 46% f 12% or 25% f 5% for bolus injection of 1 mgikg Actilyse or rt-PA del(K296-G302), respectively. After prior bolus injection of 1 mgikg reactivated rPAI-1, no lysis was detected in the experiments with saline or Actilyse. At 90 minutes, the measured radioactivity was actually somewhat higher than at the beginning of the experiments. Bolus injection of 1 mgikg rt-PA del(K296-G302) after prior bolus injection of rPAI-1 still resulted in significant clot lysis as monitored by external gamma counting (15% ? 1% at 90 minutes). Table 6 also summarizes the levels of t-PA-related antigen (in micrograms per milliliter), PAI-1-related antigen (in micrograms per milliliter), and t-PAIPAI-1 complex (in micrograms of PAI-1 per milliliter) measured 1 minute and 30 minutes after the bolus injections. Immediately after bolus injection of 1 mgikg rPAI-1 (total protein about 3 mgikg), PAI-1-related antigen increased to approximately 30 )*g/mL; after subsequent bolus injection of 1 mgikg rt-PA del(K296-G302) or Actilyse, t-PA-related antigen increased to between 5 and 10 FgimL and t-PAIPAI-1 complex to 5.3 pg/mL (micrograms PAI-1 per milliliter) for Actilyse but to only 1.8 kg/mL for rt-PA del(K296-G302).
Thus, on a molar basis, 1 minute after bolus injection all the t-PA-related antigen in plasma was complexed with rPAI-1 for Actilyse, but only 26% was complexed for rt-PA del(K296-G302). Figure 9 shows the t-PA-related and the t-PAIPAI-1 antigen levels as a function of time (0 to 10 minutes) for bolus injections of rt-PA del(K296-G302) or Actilyse in hamsters supplemented with rPAI-1. Table 7 summarizes relevant pharmacokinetic parameters describing the disposition of single-chain rt-PA del(K296-G302), wildtype rt-PA, or Actilyse from blood after bolus injection at a dose of 0.10 mgikg in groups of three hamsters.
The plasma concentration of t-PA-related antigen after the bolus injection (C,) increased to 1.3 0.07 pg/mL for rt-PA del(K296-G302), as compared with 0.96 f 0.12 or 1.2 f 0.06 FgimL for wild-type rt-PA or Actilyse, respectively. The disappearance rates of t-PA-related antigen (Fig 10) could be described by a sum of two exponential terms by graphical curve peeling. This yielded the coefficients and exponents reported in Table 7 together with the derived pharmacokilletic parameters. The results indicate that all three rt-PA moieties have a rapid clearance of about 2 mL/min as a result of a short initial t% of 1.0 to 1.4 minutes.
Plasma clearances derived from the steady state t-PArelated antigen levels during the 60-minute infusion in the thrombolysis experiments ranged between 2.2 and 2.3 mL/min for different doses of single-chain rt-PA del(K296-G302), between 1.3 and 2.8 mL/min for wild-type rt-PA, and between 2.3 and 3.2 mL/min for Actilyse.
Pharmacokinetic properties in hamsters.
DISCUSSION t-PA is rapidly inhibited in human plasma by a specific rapid reacting inhibitor, PAI-1, which is present in normal plasma at a very low c~ncentration.~ In several pathologic conditions, including patients with coronary artery disease3' 32 and acute myocardial infarction," 34 significantly enhanced levels of PAI-1 have been reported. Plasma concentrations of t-PA achieved during thrombolytic ther- For personal use only. on November 11, 2017. by guest www.bloodjournal.org From The data represent mean f SEM of three experiments.
*C, represents the t-PA-related antigen concentration in a blood sample taken 30 seconds after bolus injection.
apy in humans are several hundred fold higher than the plasma concentrations of PAI-1 activity. In addition, t-PA has a short half-life in humans, of the order of 5 minutes,15
mainly as a result of rapid hepatic clearance. These findings suggest that inhibition of t-PA by PAI-1 in circulating blood would not significantly affect the outcome of thrombolytic therapy. However, in as far as high PAI-1 levels may contribute to the occurrence of reoccl~sion,~~ PAI-1-resistant mutants of t-PA may be useful for maintenance infusion after initial thrombolysis.
Madison et a17 have reported that substitutions or deletions in the region comprising residues 296 to 304 of t-PA confer resistance to PAI-1 as well as to the complex mixture of serpins in human plasma in vitro, without affecting the activity towards plasminogen. A mutant in which the three positively charged amino acids in this region are replaced by glutamic acid residues (t-PA K296E R298E R299E) was shown to be extremely resistant to inhibition by PAI-l. 37 The region of PAI-1 that is proposed to interact with the 296 to 304 loop of t-PA contains three acidic residues (G1u3", G1u3", and Asp355). Interestingly, substitution of GIu3j0 or Glu3" by Arg (PAI-1 E350R or PAI-1 E351R) generates a serpin that efficiently inhibits both wild-type t-PA and serpin-resistant t-PA. These results suggest that the contact between t-PA and PAI-1 is mediated by electrostatic interactions between loops of amino acids located on the surface of both proteins.38
In the present study, we have constructed an rt-PA mutant, obtained by deletion of residues Lys"' to Gly302 [rt-PA del(K296-G302)], confirmed its biochemical properties, and evaluated its biologic properties in a plasma milieu in vitro and its thrombolytic and pharmacokinetic properties in vivo in a hamster pulmonary embolism model.
Purified rt-PA del(K296-G302) was obtained as a singlechain molecule with amidolytic activity against a chromogenic substrate for t-PA that is comparable with that of wild-type rt-PA. Its catalytic efficiency for plasminogen activation in the absence of fibrin and stimulation of the initial activation rate by fibrin were, however, significantly lower than those of wild-type rt-PA (Table 1) . Prolonged activation of plasminogen (1 pmol/L) in the presence of CNBr-digested fibrinogen (2 pmol/L) showed a lag phase for both single-chain and two-chain rt-PA del(K296-G302) and a plasminogen activating potential that was twofold to threefold lower than that of wild-type rt-PA or Actilyse, respectively (Fig 2) . This finding is in contrast with the report of Madison et al' that a similar mutant has unaltered affinity for plasminogen. These studies were, however, performed using Lys-plasminogen instead of native Gluplasminogen, and with only one (saturating) concentration of desAAfibrin as stimulator. In agreement with the findings of Madison et al,' the inhibition rate of rt-PA del(K296-G302), both in its single-chain and two-chain form, by PAI-1 in purified systems was several hundred fold lower than that of wild-type rt-PA. If added to plasma at low concentrations, complex formation of the mutant with PAI-1 was indeed found to be impaired as compared with wild-type rt-PA. However, when added to plasma at concentrations such as those achieved during thrombolytic therapy, the half-life of t-PA activity was not significantly different from that of wild-type rt-PA, indicating that under these conditions the mutant rt-PA is inhibited by the plasma protease inhibitors. These findings also suggest that rt-PA del(K296-G302) is a specific PAI-1-resistant variant that reacts normally with other serpins.
In a human plasma milieu in vitro, equi-effective concentrations (causing 50% clot lysis in 2 hours) were comparable for mutant and wild-type rt-PA (0.28 and 0.36 p,g/mL, respectively). Reduction of the fibrinolytic activity to 50% was achieved by the addition of 15-fold lower concentration of rPAI-1 for wild-type rt-PA as compared with rt-PA For personal use only. on November 11, 2017. by guest www.bloodjournal.org From del(K296-G302), confirming the resistance of the mutant to PAI-1 in a plasma milieu.
In a hamster pulmonary embolism model, the thrombolytic potency (clot lysis per unit dose) and the specific thrombolytic activity (clot lysis per unit steady state plasma level of antigen) were not significantly different from those of wild-type rt-PA. As observed previously in this model,' our homemade wild-type rt-PA is about twofold less active than Actilyse; therefore, the results obtained with the mutant are compared with those obtained with wild-type rt-PA that is produced in the same expression system. In hamsters supplemented with PAI-1 by bolus injection of 1 mgikg reactivated rPAI-1 immediately before bolus injection of rt-PA del(K296-G302) or Actilyse, the thrombolytic potency of 1 mgikg Actilyse was virtually abolished, whereas 1 mg/kg rt-PA del(K296-G302) retained approximately half of its thrombolytic potency.
These results suggest that, in the presence of high PAI-1 levels, the thrombolytic potency of rt-PA del(K296-G302) is superior to that of wild-type rt-PA, whereas in the absence of PAI-1 both are equipotent. Whether the clinical use of such PAI-1-resistant rt-PA mutants would be associated with less PAI-1-mediated reocclusion after thrombolysis and/or with a better thrombolytic potency towards plateletrich blood clots (with high PAI-1 levels) remains to be investigated.
